title: Osteonecrosis after administration of intravitreous bevacizumab.
authors.affiliation: Department of Oral Diagnosis, Piracicaba Dental School, Campinas State University, Piracicaba, São Paulo, Brazil. renhopp@gmail.com
authors.forename: Renato Nicolás
authors.initials: RN
authors.lastname: Hopp
authors.forename: Juliana
authors.initials: J
authors.lastname: Pucci
authors.forename: Alan Roger
authors.initials: AR
authors.lastname: Santos-Silva
authors.forename: Jacks
authors.initials: J
authors.lastname: Jorge
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D002710:Chlorhexidine / Q000008:administration & dosage; D002981:Clindamycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D058449:Intravitreal Injections; D007571:Jaw Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes; D010020:Osteonecrosis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D061067:Antibodies, Monoclonal, Humanized; D009067:Mouthwashes; D000068258:Bevacizumab; D002981:Clindamycin; D002710:Chlorhexidine